Bausch & Lomb
This article was originally published in The Gray Sheet
Executive Summary
December launch is planned for the firm's 25-gauge entry site alignment (ESA) device for use with the Millennium TSV25 system for transconjunctival standard vitrectomy, following 510(k) clearance of the component, announced Oct. 29. The system is used to correct retinal detachments, macular degeneration and diabetic eye diseases with incisions about half the size of standard incisions, according to B&L. Separately, the firm has agreed to license worldwide rights to Largo, Florida-based Unilens Corp.'s cast-molded, multifocal soft contact lens design. Under the agreement, B&L will develop, manufacture and market the device for frequent replacement, and pay a royalty ranging from 3-5% of sales. Distribution will begin within the next year, pending FDA approval...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.